NOT MEDICAL ADVICE

CJC-1295 (no DAC)

Estimated Market Price
$109.99 $124.99
Based on verified supplier pricing for research-grade compounds
Growth hormone releasing hormone for enhanced recovery, sleep quality, and body composition. Pairs perfectly with Ipamorelin.
How it works

Stimulates your pituitary gland to release more growth hormone in natural pulses, amplifying your body's own repair and recovery cycle. Modified for longer activity than native GHRH.

Growth Hormone

Performance

popular

What to Expect
Week 1–2 GH pulses increasing; improved sleep depth and recovery. Sleeping deeper; waking up feeling more rested.
Week 3–4 Fat metabolism shifting; subtle body composition changes. Recovery from workouts faster; skin looking better.
Week 5–8 IGF-1 levels optimizing; skin and hair quality improving. Leaner look; hair and nails growing faster.
Week 9–12 Peak GH optimization; reassess labs and protocol. Overall vitality up; feeling younger and more resilient.

Verified Suppliers

For research purposes only. These suppliers have been independently verified by PepSpace. We do not process sales directly.

PepSpace is not affiliated with any listed supplier
Protocol & Dosage
Typical Dosage 100–300 mcg SC per dose
Administration Subcutaneous injection
Schedule 1–3x daily; commonly before bed and/or pre-workout
Protocol Duration 8–12 weeks
Half-Life ~30 minutes
Side Effects & Safety
Tolerability Profile Mild

Generally well tolerated; side effects are mild and transient

Common Side Effects

  • Injection site redness or swellingmost users
  • Mild water retentionsome users
  • Temporary flushing or warmthsome users

Less Common

  • Headacheoccasional
  • Vivid dreamsoccasional
  • Mild joint stiffnessoccasional
  • Tingling or numbness in extremitiesoccasional

Rare / Serious

  • Elevated fasting blood sugarrare

Discontinue If

  • Carpal tunnel symptoms (hand numbness, weakness)
  • Persistent joint pain or swelling
  • Signs of elevated blood sugar (increased thirst, frequent urination)

Contraindications

  • Active cancer or tumors
  • Diabetic retinopathy
  • Pregnancy or breastfeeding

Data note: Preserves natural GH pulsatility (unlike DAC version). Research compound; no completed Phase III trials. Best studied in combination with ipamorelin.

Always consult a qualified healthcare professional before use. This information is for research reference only and does not constitute medical advice.

Ask about CJC-1295 (no DAC)
Send us a message

Call us
+1 (518) 327-4392
Business hours
Monday – Friday 9:00 AM – 6:00 PM EST
Saturday 10:00 AM – 2:00 PM EST
Sunday Closed

You can also reach us via or .

How to Apply

1

Gather

Peptide vial, BAC water, alcohol swabs, insulin syringe

2

Sanitize

Wipe tops of both vials with alcohol swabs

3

Draw

Pull 1–2 mL of BAC water into syringe

4

Add Water

Release water slowly along vial wall, not directly on powder

5

Swirl

Roll between palms until dissolved. Never shake.

6

Store

Refrigerate 2–8°C, use within 30 days

Frequently Asked Questions

Yes. Bacteriostatic water (BAC water) is required to reconstitute lyophilized (freeze-dried) peptides. It contains 0.9% benzyl alcohol which prevents bacterial growth, keeping your reconstituted peptide safe for multiple uses over up to 30 days.

Unreconstituted: store at -20°C (freezer) for long-term, or 2–8°C (fridge) for short-term. After reconstitution: always refrigerate at 2–8°C and use within 30 days. Keep away from direct sunlight.

Results vary by individual and protocol. In research settings, measurable effects are typically observed within 1–4 weeks depending on the specific peptide, dosage, and application. Consult a qualified professional for guidance.

Verified suppliers typically include a full third-party COA verifying purity (99%+), identity, and sterility. We recommend only sourcing from vendors that provide batch-specific testing data.

We list verified suppliers above that have been independently reviewed for product quality, testing transparency, and shipping reliability. Always verify COA data before sourcing.

Compound Profile

Scientific data & classification for CJC-1295 (no DAC)

Also Known As Modified GRF(1-29), Mod GRF 1-29, CJC-1295 no DAC
Classification GHRH Analog · Growth Hormone Releasing
Sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ (29 aa)
Molecular Formula C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight 3,367.97 Da
CAS Number 863288-34-0
Half-Life ~30 minutes
Origin Synthetic modified analog of GHRH(1-29)
Administration Subcutaneous injection
Status Research compound
Mechanism of Action Stimulates your pituitary gland to release more growth hormone in natural pulses, amplifying your body's own repair and recovery cycle. Modified for longer activity than native GHRH.
Research Overview Modified GRF(1-29), commonly known as CJC-1295 without DAC or Mod GRF 1-29, is a synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH) - the hypothalamic peptide that stimulates pulsatile growth hormone secretion from the anterior pituitary gland. The peptide was developed through systematic modification of the native GHRH(1-29) sequence at four positions that are vulnerable to enzymatic degradation: position 2 (Ala→D-Ala, protecting against DPP-IV cleavage), position 8 (Asn→Gln, preventing asparagine deamidation), position 15 (Gly→Ala, reducing peptide bond hydrolysis), and position 27 (Met→Leu, preventing methionine oxidation). These substitutions dramatically improve metabolic stability, extending the functional half-life from the native peptide's approximately 7 minutes to roughly 30 minutes while preserving full biological activity at the GHRH receptor. The pharmacological rationale for using Mod GRF 1-29 centers on its ability to amplify natural growth hormone pulsatility rather than overriding it - the peptide enhances the amplitude of existing GH pulses without disrupting the ultradian rhythm of secretion, which is considered physiologically important for maintaining GH receptor sensitivity and downstream signaling through IGF-1. In research settings, Mod GRF 1-29 is frequently combined with growth hormone-releasing peptides (GHRPs) such as ipamorelin or GHRP-6, which act through the ghrelin receptor pathway - the synergistic effect of simultaneously stimulating both GHRH and GHS receptor pathways produces GH release significantly greater than either peptide alone, reflecting the complementary mechanisms at the level of the pituitary somatotroph cell where GHRH primarily increases cAMP and GHRPs primarily activate protein kinase C and IP3 signaling cascades. This combination approach has become one of the most widely studied protocols in growth hormone optimization research.

Citations

Published findings on CJC-1295 (no DAC) from peer-reviewed journals.

Research Assistant
Hey, I'm the PepSpace research assistant. Ask me anything about peptides and I'll do my best to help.